Gemphire Therapeutics – $30 Million IPO
San Diego – August 22, 2016 – Cooley advised the underwriters on Gemphire Therapeutics Inc.'s $30 million initial public offering. The company's common stock now trades on The NASDAQ Global Market under the symbol "GEMP."
Jefferies and RBC Capital Markets acted as joint book-running managers for the offering. Canaccord Genuity acted as co-lead manager and Laidlaw & Company (UK) Ltd. and LifeSci Capital acted as co-managers.
Gemphire is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease, and nonalcoholic fatty liver disease.
The Cooley corporate and securities team advising the underwriters included Div Gupta, Charlie Kim, Nicole Brookshire, Siana Lowrey, Kristin VanderPas, Jonie Kondracki, Susan Walker and Adrienne Directo.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900 lawyers across 12 offices in the United States, China and Europe.
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.